Back to results
US 12,111,318 B2Granted
Method for treating cancer based on expression levels of translationally controlled tumor protein (TCTP)
AssigneeKorea University Research and Business Foundation
InventorsTae Woo Kim, Hyo Jung Lee
Life of this patent
Estimating the term…
Abstract
Disclosed herein are a method and a biomarker for predicting efficacy and prognosis of or resistance to an immunotherapy. The use of the biomarkers (TCTP, EGFR, AKT, MCL1, and/or CXCL10) of the present disclosure allows the prediction of resistance to or prognosis of a cancer immunotherapeutic agent and the selection of a therapy guaranteeing therapeutic benefit, thereby finding advantageous applications in treating cancers or tumors resistant to cancer immunotherapeutic agents.
Claims5
A method for treating cancer comprising:
- (a) measuring presence or expression of TCTP (translationally controlled tumor protein) at a protein or gene level in a sample isolated from an individual suffering from the cancer;
- (b) identifying the individual whose sample having a higher presence or expression level of the TCTP protein or gene measured in step (a) compared to the presence or expression level of the TCTP protein or gene measured in a reference sample;
- and
- (c) administering a pharmaceutical composition comprising an immunotherapeutic agent and a TCTP inhibitor as an active ingredient to the individual identified in step (b).
1 more element
Dependencies are inferred from the claim text.